Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report) – Stock analysts at Zacks Research boosted their FY2026 earnings estimates for Oramed Pharmaceuticals in a research note issued to investors on Thursday, June 18th. Zacks Research analyst M. Marin now expects that the biotechnology company will earn $1.24 per share for the year, up from their prior estimate of $0.71. The consensus estimate for Oramed Pharmaceuticals’ current full-year earnings is $0.71 per share.
Separately, Weiss Ratings upgraded shares of Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 11th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Oramed Pharmaceuticals presently has an average rating of “Hold”.
Oramed Pharmaceuticals Trading Up 3.1%
Oramed Pharmaceuticals stock opened at $4.30 on Thursday. Oramed Pharmaceuticals has a 1-year low of $1.98 and a 1-year high of $5.01. The firm has a market capitalization of $176.00 million, a PE ratio of 1.66 and a beta of 1.26. The firm’s 50 day simple moving average is $3.99 and its 200 day simple moving average is $3.55.
Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) last issued its quarterly earnings data on Friday, March 27th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02.
Institutional Investors Weigh In On Oramed Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of ORMP. Kathmere Capital Management LLC bought a new stake in Oramed Pharmaceuticals during the first quarter valued at approximately $51,000. OMERS ADMINISTRATION Corp bought a new position in shares of Oramed Pharmaceuticals in the 1st quarter worth $63,000. Redwood Family Wealth LLC bought a new position in shares of Oramed Pharmaceuticals in the 4th quarter worth $66,000. XTX Topco Ltd raised its position in shares of Oramed Pharmaceuticals by 59.9% during the 4th quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 14,297 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in shares of Oramed Pharmaceuticals during the 4th quarter valued at $119,000. 12.73% of the stock is owned by hedge funds and other institutional investors.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.
The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.
See Also
- Five stocks we like better than Oramed Pharmaceuticals
- Washington’s Quantum Push Puts IBM and IonQ on the Throne
- FedEx’s Earnings Drop May Be Missing the Bigger Freight Story
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
